Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients

NCT04616209 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

BIOLOGICAL: donor-derived NK cell infusion

Sponsor

Precision Biotech Taiwan Corp.

Collaborators

[object Object]